Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LY 03020

Next Previous
Drug Profile

LY 03020

Alternative Names: LY-03020

Latest Information Update: 16 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Luye Pharma Group
  • Class Antidementias; Small molecules
  • Mechanism of Action 5-HT2C serotonin receptor agonists; Trace amine-associated receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease; Schizophrenia

Most Recent Events

  • 13 Feb 2025 Luye Pharma Group completes a phase I trial for Schizophrenia and Alzheimer's Disease (In volunteers) in China (PO, Controlled-release) (NCT06556966)
  • 14 Jan 2025 Preclinical trials in Schizophrenia in USA (PO) before January 2025
  • 14 Jan 2025 US FDA approves IND application for LY 03020 in Schizophrenia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top